Get to know our clinical trials
Ensayo clinico de investigación para evaluar ro7567132 con o sin atezolizumab (tecentriq®) en participantes con tumores sólidos que son inoperables y/o se han diseminad
THE PURPOSE OF THIS STUDY IS TO TEST WHETHER RO7567132, GIVEN AT DIFFERENT DOSES ALONE OR IN COMBINATION WITH ANOTHER DRUG CALLED ATEZOLIZUMAB, HAS ANY EFFECT (GOOD OR BAD), AS WELL AS WHAT HAPPENS TO RO7567132 ONCE IT IS IN THE BODY AND WHAT RO7567132 ALONE OR IN COMBINATION WITH ATEZOLIZUMAB DOES IN THE BODY AND THE TUMOR.
Technical Summary
- MULTICENTER, OPEN-LABEL, RANDOMIZED, DOSE-ESCALATION PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF RO7567132 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS.
- Code EudraCT: 2024-512839-70-00
- Protocol number: BP44956
- Promoter: Roche Farma, S.A.
- Molecule/Drug: RO7567132
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.